Focused on solving unmet needs in ophthalmology

Addressing significant unmet medical needs for transformative topical therapy
image/svg+xml TABLEAU_OCULIS_07_20_VECT 2020-06-25T13:11:12+02:00 2020-06-25T13:11:12+02:00 2020-06-25T13:11:12+02:00 Adobe Illustrator 24.1 (Macintosh) 256 88 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAWAEAAwER AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAAAAAAQFAwIGAQAHCAkKCwEAAgIDAQEBAQEAAAAAAAAA AQACAwQFBgcICQoLEAACAQMDAgQCBgcDBAIGAnMBAgMRBAAFIRIxQVEGE2EicYEUMpGhBxWxQiPB UtHhMxZi8CRygvElQzRTkqKyY3PCNUQnk6OzNhdUZHTD0uIIJoMJChgZhJRFRqS0VtNVKBry4/PE 1OT0ZXWFlaW1xdXl9WZ2hpamtsbW5vY3R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo+Ck5SVlpeYmZ qbnJ2en5KjpKWmp6ipqqusra6voRAAICAQIDBQUEBQYECAMDbQEAAhEDBCESMUEFURNhIgZxgZEy obHwFMHR4SNCFVJicvEzJDRDghaSUyWiY7LCB3PSNeJEgxdUkwgJChgZJjZFGidkdFU38qOzwygp 0+PzhJSktMTU5PRldYWVpbXF1eX1RlZmdoaWprbG1ub2R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo +DlJWWl5iZmpucnZ6fkqOkpaanqKmqq6ytrq+v/aAAwDAQACEQMRAD8A9U4q7FXYq7FUr1jUfL/o XGm6lqFvb/WImjlikmjjfhIpU7MQRUHJCJPIMJTiOZY02j/l18Ij1qOFEpwjS/TipUsVIDM2686D 2AyXDLuR4sO8fNzRfl2Lf6sPMkMYEplLLqECycjQbvXltSn+2anw59x+TH8xj/nR+YUZvL35bzNz bXFrQKpGoRmirSgBJJoCoODhl3MvEh3j5pzo135M0kz/AFbW7dhcMGdZbyJwCK/ZHL4a8t/HAYS7 l8WHePmra7P5R1Wzt47/AFSCOHn9YtpEukiJZQ8XJWDbgVYbd8RCXck5I94SOTRPIDqaeYAGo3ps b+NuDsFHNeTH4vgrXDwy7keLDvHzWQ+X/wAvYzG7eYA8yRiIy/pBFLKCCR8LDYldx0x4Zdy+JDvH zRcdj5ASD0v03Gx9RJVla/QyK0Ssq0flUfbJ+ePDLuXxYd4+aFOgfl0V4HXV4VDOn16LizCu7ivx da77Y8Mu5fEh3j5rpNE/L54vSPmD4eLKT+kIySHPIj4iceGXcviw7x82QyeZPLEk8iNq1n6bxcSf rEXckEV5YPDl3FfFh3hIotJ/LuKL0k1tAq09I/pBaxhVCgIee3TDwy7l8WHePmpS6D+Xcob1NeVi xDFjfxV5KSQw32NT1H6seGXcviQ7x805sdS8oaZYXFvbazbyLIXk/e3iStyZQDQsxO9K/PAYS7l8 WHePmu1m+8k6xaLa32qWbwq6yhVuol+Ja8TUN2riIS7iviw7wlUOmeQYp0mTXx+7YOkR1BPTFFCc ePL7PEUph4Zdy+LDvHzTlvMHlaDTRbQ6tZlIo1jjX6zETRQAP2vbB4cu4r4sO8KOtXnkbWraO21D U7OSKN/VRRdRL8XBkrs3g5xEJdxXxYd4SyLTPISPIzeYBL6sckUiy6gjhlmWRWqC3X981Dh4Zdy+ LDvHzTq31vyrbafBY2uq2jJAkcECfWImYhAEUfa3O2Awl3J8WPeF+s+UdI1a6+uXPqx3YiECzwyN G6oOewI6V9VgfHIgs0FL+XmgzWklrPJdTQyyrORJOzEOnqU416f3zVx4lpONS0qy1MPa3iGSEelJ xBI+JGZl3HgRgVKh5B0YRMgnvAW51cXD8qSVqB7DkafPDarZvy90CaL0pWuXUhgeUzb8nZ2Y9ixL nc748S02v5f6KCSZ7xiSSxa4Ykgrw4luvGnauNqjNM8uWekNLLBPcyvOY1c3EzS7CUttX3kOJKpz gV2KuxVbL6npP6dPU4nhXpyptir4z1NtQbUbo6jz/SHqv9b9WvqeryPPlXvyzoI1W3J4jJxcR4vq 6sgW3/L0xJ/pNyHMRMvLkSJOD8eCrEA3xceQLADsxGU3kc0R01cz+PglutJ5XW1txpD3Elzsblp6 BfsD7KhRT4q13Pt4myHHfqaM4xUOC7SfLHGdirNzF5bk0byyPME1zBajTbkwtaBS5m/Sc1AwYMOP Dl/nsca5cUuHvH3OyAxmEPEJA4Zcv6yjJZ/lWlvyjvtTmnCt8BWOMFgvw7+nJSrfhh4svcEGGlr6 pfj4KdvZ/lkZJ/rF/qSRAJ9W9NI2ZtlL86ooH7QA+W+Jll7ggQ03WUvx8GhZflsWSuoX6ID+9PBW Yrv9gcFFTUdTtvudjjxZe4L4em/nS/HwVILL8rvWm9e/1L0RMBAUVORhpDUtWOleRm+gLt2KZZe4 KIaazcpfivL3oHXLXyNHp6to15ezahVC6XCIIqfF6gBAU914/Jq9RkoHJfqAprzQwCPoJMvNjuXO G7FXYq7FXYq7FXYq7FXYq7FX1L+U03muXyhbN5hSjigsXcn13t6fCZQe/gepHXxOl1Ijx+l67QHI cY4+f215szzHcxJfMo1A2zfUBOZxxP8Ao5AfiFk/mNDTsPGmx6YQqQf87Dcx/GdYRvQYqAIYjz9Q vUlT9orRQPo264VU7SfzWZF9f9KsPimC+nAoDVJSNj9FDsRuMdkOc+bHURtJqsU3GQsyRW5QFFZk Aav7RAHQ1x2VkmkWeowWonvb2a4a4FuRBOqKYTzLMvw0qfjAPywFKc4FdirsVad1jRnc0VAWY+w3 OKvmLzT+aMutavNdro2melUrC1xapNOUGy+pI3U0+gZucem4RVl5fP2hxyvhjXmLKoP8VEIf8OaP WRWeNfQtOTBFLOFXnyJUKeS0qOh6jI+j+dL7Wysv+pw+Q/WleqS6/pkcN1faPp8EVwaxD6vbNXYN TivJhSvf5dQcsiIy2BLTllkgLlCAvyCh/jSX/qzaR/0hR4fB85fNr/Of0If6V3+NJf8AqzaR/wBI UePg+cvmv5z+hD/Ssrlv9a1XS/LsOl6Fp15cyWFzO0H1WIhFS+mjPphiAB02HUnKOERMrJG/6HN4 5zhDhhEmj0/pIO3tvOtzIYoPKemyuFVyFs4D8L8+P7Xf0X+7JEwH8R+bERzE14cPkP1qh0/zyCgb ynpimTj6fK0tl5cg7LSrb1ETfdg4ofzingzf6nD5D9ajLD5yieJH8q6ZymZkjC2cDVZIzKw+FjuE Uk/KnXCDD+cfmxMcw/ycN/IfrVJ7LzvBMIZvKemJKeZCG0t6/ulDN0bwYEePbAJQ/nH5pMMw/wAn D5D9ax7fzmk6wP5U0wSuzxqhs4KlowS4+12C4bh/OPzXhzf6nD5D9a1I/Nr3xtF8s6SbgRvJw+rW 1OERUMwbnxP21779sfRV8UvtRWW68OF+4frVWsvPCStC3lLTVlUVZDZwVFQWFfi7gbDvg4ofzj80 8Gb/AFOHyH61P0fOH1eK4/wvpXpTRiaJvqttVozT4gOVduQ5eFd8Nw/nFHDmq/Dh8h+tbEnm+eC2 lTyvpnpXqhrZzaQLzVo2lBXkw/YQnE8H84/NYjKQCMcN/IfrVUtPOrwidfKml+kY/VDG0tx8FGPL dv8AIONw/nH5p4M3+pw+Q/Wl2satrejTrBqXl/SbeZwxVDaQMaKxRvslujKR9GThCMuUpfNpy5Z4 zUoQHwCXnznKRT9D6SPlZR5LwfOXzavzn9CH+lb/AMaS/wDVm0j/AKQo8fB85fNfzn9CH+ld/jSX /qzaR/0hR4+D5y+a/nP6EP8ASro/PE8cqSLo+kho2V1IsoxupricPnL5pGtIN8EP9K+lPJfnPSvN mjrqFieEi0S7tWNXikpXifEH9lu/4ZqMuIwNF6bTaiOWPFFP8qb0DqGofUi0v1ae6qEX07ZPUcV5 mpFRt8OKoJvNAoSmk6lIQnMgWxX9vhT42WrbcqeGGldF5qikdUGmaktWKlmtJFAAPHkSabY0qybz fDEoZtL1Mk1ARbVyx41rRQan7P6saVF2mrpqHqILS6tvRaElrqFoQ3KQiiFvtU4b08RjSpInmPzz Vg/lrlVY2XjcItCePqIa1BpUgNsNq4aCFf8AxD5tJVh5dYR+rwdTMhYRjlVx0rWgoOu+CglW0DzJ repXr295oFxpsKA8riZwV5hUPEDivIHmRyWo+HEhDISAQQRUHYg4Evmjzb5L8hWOvXdta+a4baNH NbV7e4nMJrvH6sKurceniO+bfFmyGO8XmdTpcEZkCdeVE18kL9W0n0/T/wCVgfu+Aj4ehqXHgoIC 04dACdslZ/mfcx9P+rH5SQVxpOi3HFZ/OdvNGlAgkg1FqKo4rQGA0oopkhKQ/g+5rlCB55b+Emv8 NeTv+pwtv+kK+/6pY+JP+b9oR4GH/VP9iXf4Z8nf9Thbf9IV9/1Sx8Sf837QvgYf9U/2JZBq2j+X Y9E8ucfNsVqsVpOsNwtte/vVN7M5YBI+ShX+GjdxXwyqMpcUvT93c5U8eMQhWStjvR33SlNN0FFC p57VVXlxAttQAHM8mpSP9o7nLOKX8z7mkRgP8t9knHTtBJUnz4pKV4n6tqO1etP3eC5fzPuWof6t 9klv6K8vcg3+Ok5ClD9W1Co4ii/7r7DYYeKX8z7l4Yf6r9km20zy+7Kzee0Zk3RjbagSOh2/d/5I x4pfzPuUxh/q32SWvpHlt6c/PEbUpStrqBpTp/uvHil/M+0IMYf6r9klxsNEYtG3nsFCCSTb6gQS xNRTh7n78Fy/mfcmof6sflJv9G6By5/47TnSnL6tqFaUp19Pww3L+Z9y1D/Vvsk5dN0BE9NPPaKl AvAW2oAUAoBT0+w2x4pfzPuURgNvG+yTnsNDIZj57V23NPq+oVJII7p3qcFy/mfctQ/1Y/KTYsdE FSPPo+Kpb/R9R3r1r+7xuX8z7lqH+rH5SUJtA8qzPzm86QSv05PaX7GnzMeSE5j+D7QwlixHnlv/ ADZKT+W/J4Ukeb7diOiiyvd/vjx8Sf8AN+0I8DD/AKp/sS3/AIZ8nf8AU4W3/SFff9UsfEn/ADft C+Bh/wBU/wBiU78t/lNZeZPWGi+ZrS7a3p6yehPGyhuh4yqhI9xleTVGH1Rb8PZ0cv0TBryTs/8A OOurpRpNYgKAjnxjetK70qcr/Pjucgdin+d9j2by55c0ry9pUWmaZF6VvFuzHd3c/ad27sf89s18 5mRsu6xYo448MeSZ5BsS/UtKsdUL217H6sICOFqR8VJFrUdxyxVBw+TNBijCLHKwCGL4ppTVT41b fx3774bVSTyF5bQqUhlHGMxbTSgFWDBqgNvy5mv9mNrSoPJPl4MSsMi1WReKzSKtJVZGHENx6Oe2 NqmqW0NrZQW0QpDAIo4wTWioVVdz8sCojFXYq7FVsqs8TqrcGZSFbwJHXFXx9rXlnXtI1Kexv7OV LiJiCeDFXFftq1KMp7HN9DJGQsF43LpskJEEFPF1bRfSVD5YcMsPBmABLuVYcqtGePEkUO5P7Vcq 4ZfznMGWFf3fT8dEt1vUtHu7CG3sdIawuomX1ZahuQVOJGyI1S3Wv661nCJBsm3Hz5ISiBGHCUn+ oX3/ACzy/wDAN/TLeId7j+FPuLf1C+/5Zpf+Ab+mPEO9fCn3Fmbva2ej+WpNS0h9Ti/Rt0iW9Xj4 SnUZmVyVBP2QdvfMbnKVGtx9zsRUYQ4o8Xpl/uln6X8q+oCfKD+nyjYp6ktQq/aUNT9rxOPDL+cn xMX+pFh5sL6u1tLT/Ub+mZPEO91vhS7i76hff8s0v/AN/THiHevhT7i76hff8s0v/AN/THiHevhT 7i76hff8s0v/AADf0x4h3r4U+4u+oX3/ACzy/wDAN/THiHevhT7i76hff8s0v/AN/THiHevhT7i7 6hff8s0v/AN/THiHevhT7i76hff8s8v/AADf0x4h3r4U+4u+oX3/ACzS/wDAN/THiHevhT7i76hf f8s0v/AN/THiHevhT7i76hff8s8v/AN/THiHevhT7i76hff8s0v/AADf0x4h3r4U+4s6/KDyt5ov PNUN9YvLp1rZEG8uytAUO5h4ts5fw7dfDMXVZIiNHe3YdnafIcnELiBz/U+krj+5b6P15qHplTFX Yql+pWEt7zhjupbNgFb1YTRukgA+VSD9GKoOHQNWSMLJrtzK3AozcIlq3Ztl2of86YbVSj8s6upU HzBdsojMbghKsWDAvWlQdxSnSnzxtVQeXtVBIXXbr0ysi8CqE/GrKDyI5VUtUb9sbVMba2ltbCG3 muHupI2UGeSnNv3gpWncDbAqMxV2KuxVbK/pxPJQtwUtxHU0FaYq+V9W/NXz1qF/LdDVp7RJGJjt rdzHGi12UBaVp4nfN3HTQAqnk8naOaRsGk+WX8xzCkn+LHIkiMyhZ5iAAjNR2KhVrw+Ek0bqDlP7 v+a5ojqKvxEr1vVfP+l2UF5L5ouphcFaJDdztx5IH3NeP4+42ycI45GuFx85z44iRmTfmUp/5WL5 7/6v17/yOf8Arln5eHcHH/PZv5xb/wCVi+e/+r9e/wDI5/64/l4dwX89m/nFl41vz3qul+X0sdfk tbiTT7i5uZZ7lohIU1CWEVberceIHsMx+CETKx1/Q58cmbJGHDKjRJ/01IdpvzLE8sP+LVLQkByL ySnIq7cQePZYifu8cP7r+b9i8OpuvEHz/Y1HP+ZzrX/FXFuTKY3vHVvhd467gdTE1P7Rj+6/m/Yo jqf54+f7ETJbfmogJ/xbExrQAagak8+HcCm/jTBeL+b9jI49V/PHz/YkWv8Amf8AMXRNQNlc+Y55 5AocSW1y0kZBJGzbfy5bjx45CxFxM+fPilwmfyS3/lYvnv8A6v17/wAjn/rk/wAvDuDT+ezfzi1/ ysPzzy5fp295UpX1m6ffj+Xh3Bfz2b+cW/8AlYvnv/q/Xv8AyOf+uP5eHcF/PZv5xd/ysXz3/wBX 69/5HP8A1x/Lw7gv57N/OLR/MTz0QQddvSDsR6zf1x/Lw7gv57N/OLf/ACsXz3/1fr3/AJHP/XH8 vDuC/ns384u/5WL57/6v17/yOf8Arj+Xh3Bfz2b+cWm/MPzywIbXb0g9QZm/rj+Xh3Bfz2b+cW/+ Vi+e/wDq/Xv/ACOf+uP5eHcF/PZv5xZn+V/5s+YYdfi0zWJp9UtNQkWNWblLNFIdlZKVZl/mX6R7 4+o00eGxtTnaDtCfHwz9QL364/uW+j9eat6FUxV2KoHUbq8tg8lpaG9lov7kOI9qOa8mB8KfTiqB j1zW3Sp0KZGKFwrSxD4hWimhPUU+n78NKpxeYNfYgP5emSqFq+tGaNQlUPTrTc9q98aVUXXdcrxf Qpg/FzVZY2SqqSo5Gh+IgDp3xpUwt7i4uNPhmubc2k7snO3ZgxU+oBTkNjXAqK5t/vtv+F/rirub f77b/hf64q7m3++2/wCF/rirubf77b/hf64q8h8z/lr+VsusTyPqUumXDsWntIJImjVyamisHKb/ ALNfkBmbj1OQDlbq83ZuGUrshKf+VYflb/1MVz/wUP8AzRln5vJ3NX8lYf5x+z9SHP5bfliHp/iS 5oD09Nenz44fzWT+aj+SsP8AOP4+CI/5Vh+Vv/UxXP8AwUP/ADRg/N5O5P8AJWH+cfs/U7/lWH5W /wDUxXP/AAUP/NGP5vJ3L/JWH+cfs/UmWp/l7+XU+maRBPrlxHBaQSx2kgMVZEa4kkZj8PaR2X6M hHUzBJrm2z7OxGMQZGo+7v8Aclv/ACrD8rf+piuf+Ch/5oyf5vJ3NX8lYf5x+z9Tv+VYflb/ANTF c/8ABQ/80Y/m8ncv8lYf5x+z9Tv+VYflb/1MVz/wUP8AzRj+bydy/wAlYf5x+z9Tv+VYflb/ANTF c/8ABQ/80Y/m8ncv8lYf5x+z9Tv+VYflb/1MVz/wUP8AzRj+bydy/wAlYf5x+z9Sz/lWX5X+oV/x Dc8ONeXKHrXp9jH83k7l/krD/OP2fqX/APKsPyt/6mK5/wCCh/5ox/N5O5f5Kw/zj9n6kXpv5M/l /qcrxWGt3dxJGOTojQVCk0rQrkTrJjmAkdk4jylL7P1I+X/nHvy0kTv9evzxUmlYOwr/AC4Pz8u4 J/kfF3y+z9S7/oXjyz/y33/3wf8ANOP5+XcF/kfF3y+z9Tv+hePLP/Lff/fB/wA04/n5dwX+R8Xf L7P1Kc//ADj55aiheQX1+SorSsH/ADTj+fl3Bf5Hxd8vs/Uqf9C8eWf+W+/++D/mnH8/LuC/yPi7 5fZ+pk3kn8sPL/lK4lu7VJru9kHFLm4MZaNKbqnHiBXueuU5tTKex5OXptDDDuNz5stuHb0W/dt2 /l8fnmO5irzb/fbf8L/XFXc2/wB9t/wv9cVU1kb6w49NvsJ/L4t74qqc2/323/C/1xV3Nv8Afbf8 L/XFXc2/323/AAv9cVU5mJRQUIHNNzT+ce+KrF1TTHtzcreQNbBS5nEiFAo6nlWlN8Vai1XS5QrR XkEitXiVkQg02NKHFXDVtLaQRC8gMjVKoJE5HizK1BXsyMD7g4qreqksb+hIrNQgMpBoe3TFXzrf 2l5aXk1veo0d1GxEqv8Aa5eNT1r1r3zPBvk4BBB3Zpa3vq24V9Q01FCRxESAqSvFQSOE1dwSCTQ7 bgdcpI8i3g+YXSTuwaOTW7CSGD04nVzy9RFT0+RIlLkqrlqKdz92NeS35hI9Y0+1uXu9Sk1O3a6e srW8dDVyEJVSZHqPjI6/snJxPSmEgDvbHcsamTeto8VhobarBJPbmzl4pEeLB/r0hr1XbiGH05Xv Zpt2oWhxe+Tmjo+n3CyEUJjk2BKUqAzN+18X4Yal3ouPcpwXPlNUImtLiRuUhBDBfhNfTH2zuNv7 cSJKDFVF55MFSbC4PUAc9urUP2/ddvbr4tSTce5LdWl0qS4VtMhkgt+PxJKeTcuTHrVuikDJRvqw lXRBYWLsVdiqdeT7LW7rXbf9Dkx3UR5mY/YRBsxf/J3pTv0yEyAN2eMG9nu9xUWknI1IjbkQKCvH sKnMJzVXFXYqoXxpaSk9lxVXxV2KqdyaQsfl+vFVTFXYql2qafJfh7eO8nsmAjf1rdgr7F9qkEU+ jEKgj5ZvvUSQa5e8kkDsCw4slAGQqABvvTwJ6bDDauXyzehuTa5fsaUHxIKEEkGgWnfG1bt/Ld7F LC7a3eyrEyu8bstH4sGKtQA0NPu26Y2qdT/YH+un/EhgVJU8jeU42LR6bFG3piIMnJSFAQDiQRxY ekvxDf33OGytLW8heUW58tOUmQAO3OSpAPIb8q9cbK01J5A8oSW8Vs+ngwQR+jEgklAEfJ347Pv8 UrHf+mPEUUiNA8r6H5btJV02Axh1UzuWLO/pg8a122B7Yk2ryXVvP/mDULt5vUSKGp9GH0onCL2H J1YnMuOMBxTlJTRL93iVl1cB2jRgrWcY+NwNgREdgx65GvJnfmhmkQ8D9bZJ348uVtGVSVkLFGPp D9r4RthQhNQ1zzBBcyiF2a0Un0pntoRyQftV9OnfCIhjKUggv8Wa7/v9P+REH/NGHgDHxCyD695o 1Cx0lLBo3nazmnmBjgGyXUiVHNadKdMhUQTbZciBSkIfPzSLGqxsWFQfSt6U26kpt1w+lfW2lv59 eL1QYeHqvBUra/bRihH2f5l2OD0r610Fp+YU0SSIkfGQVXlHbKd0D7grtse/v4Y3BamsEPnw0/ug SK0KWwP2A/dfBsPpX1pbqWt+aNOvZLO7ljS4i4l1EVuw+JQy0KoQahhkhGJYGcgaQv8AivXa19dK 9P7mH/mjHgCPELf+LNd/3+n/ACIg/wCaMeAL4hTryp+YN7p+p11ErNZTgJNwjRHWhPFxwVa0r0yM 8QI2ZwykHd7BMwa0kZd1aMkfIjMRylXFXYqo3n+8snyxVWxV2Kqdx/ct9H68VVMVdiqX6pqX6OV7 g2txdika+laR+rIKlzy41GwpiqCPmxBJGp0rUVV5BF6jW/FQSBxrVtgSwFT3+WGlcPNYLUGj6nQK GLG2IHfbdhUinQY0rdv5qE8sMY0nUo2mZVDS2zIqhmA5O1SFAB5H+uNKnM/2B/rp/wASGBV+KuxV 2KuxVgepflHpVzdyT2t29pHIS3ocA6qT2U1Wgy4Zi0nCCmNv5L1K3j9OLVwqkqzH6shJZaCtS3cK Ae2A5B3MxA965vKevF5HXW0UyMGJ+pqacaFaVkP2SoPzGDjHcjhPeoXHkK7ntpLeTVR6Ui8GAtwK LRFoBzpt6QphGTyUw80p/wCVN23/AFdH/wCRI/5ryfj+TDwB3ou7/KqC4tLG2OouosoniDekDy5y vLX7W395TIjN5JOFCf8AKm7f/q6v/wAiR/zXh8fyR4A73f8AKm7b/q6P/wAiR/zXh8fyXwB3u/5U 3bf9XR/+RI/5rx8fyXwB3uH5N246aq//ACJH/NeDx/JfAHe7/lTdt/1dH/5Ej/mvD4/kvgDva/5U 3Byp+lH406+kOv8AweDx/JfAHe3/AMqbtv8Aq6P/AMiR/wA14fH8l8Ad6Z+Xvyx0vSdQW9nnN88d DAjoFVX/AJiKtUjt4ZCWYkUyjiANsxlUtE6jqykD6RlTauxV2KrJ0Z4XRepG2Kr8Vdiq2VS0ZUdT /XFV2KuxVaFPqs3YqoH0E/1xVdirsVdiqyZSyAAVPJT9AYE4qvxV2KuxV2Kscvtb8zRXF0kOmAxR cvQlIkfmVJCrRAftKOfLoPsnffDSq0ereYnuLpDpZigijZoHcgs8np8lXihZftbbN7eOKoebzPr0 UaSDQJ5PUjR+CseSM1aq3wdqf2dKtKuXzJrzeu36AnUQxllQuOUj+ssYCkLT7BLn5Y0rr/XvMsUS SWujGVzGzvByJaoYUHOirXiTt3O2w3xpW59e8x20EDvojXDzKxZIZDVCKkBhxanYde+NKsk8xeZU DgaC7kD4JFlNCSdvhKBulK+/340rUfm3Vn1A2P6DmWXiSrM5CkgO27GPiBSOla/aIAqN8aVoeZfM xgaf/D0qBS1IGkBlIUf5IK7noQTt2xpVS51vzIs86RaXwhQVhlcO9TwJCkRgncj7Q6dOuNK3+nPM ZvmhGkskHpl45HBJZhAz8SULqp9UKtCd69aimNKsl8z68ghdfL88iyxI7KGNY3MrIyt8H8gD9On0 Y0q6HzJr8jS8tAmiSOJnXk+7uJURVFF/kZnPU7UG+NKum8weYFEAj0OQvKx9RTJsi0WlWCbV57+F D1640qjp3mvWLxZH/Qc8aKJuHMsp5Q9Faqft9qV+k7Y0qo3mHzGrRoNCd5OKtKwkIT4kLUVinUbA inXb3xpW5/MPmAXtxbwaHIYIWKpdO54yAEgFUC1oaDvjSoeTzZ5hjEbN5em4kgSEOd6rUcRw6liA OX00O2NKv1PzTrumpJJLock8QneKN4HdvgDBVkcCNjRuXYfRtjStweZ/Mcqpz8uTRM4YkNNsOPYk R9T2/wBujSubzH5kMrQJoj82SJknJf01aSFXZWBVeXGQldiPemNK1c+adbtLKa4n0OZ3icp6cZO4 VCS1QHqrOvwkdiO4IxpV3+JvMBh9VNAlYM4RELlWoWoHIKfZpv2pjStalrPm6ALJZ6WlykooEoyt GfTiarcivIcndeikcfnRoKnOk3t7dwytd2jWksUrRBWJPNVAPMbDY19/mcBVG4q7FXYq/wD/2Q== xmp.iid:a9072e04-9ba8-443c-9ddd-b4515db5f093 xmp.did:a9072e04-9ba8-443c-9ddd-b4515db5f093 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:a886f36c-40c1-e64e-86ba-90c1dc26bade xmp.did:0de58a22-c0ee-4f57-bce7-2bfa08552fd0 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf saved xmp.iid:44433185-2184-4731-93c4-278700048922 2019-11-26T15:11:19+01:00 Adobe Illustrator CC 2017 (Macintosh) / saved xmp.iid:a9072e04-9ba8-443c-9ddd-b4515db5f093 2020-06-25T13:11:12+02:00 Adobe Illustrator 24.1 (Macintosh) / Print AIRobin False True 1 40.461980 14.669763 Centimeters Cyan Magenta Yellow Black Groupe de nuances par défaut 0 Blanc CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Noir CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 Rouge CMJN CMYK PROCESS 0.000000 100.000000 100.000000 0.000000 Jaune CMJN CMYK PROCESS 0.000000 0.000000 100.000000 0.000000 Vert CMJN CMYK PROCESS 100.000000 0.000000 100.000000 0.000000 Cyan CMJN CMYK PROCESS 100.000000 0.000000 0.000000 0.000000 Bleu CMJN CMYK PROCESS 100.000000 100.000000 0.000000 0.000000 Magenta CMJN CMYK PROCESS 0.000000 100.000000 0.000000 0.000000 C=15 M=100 J=90 N=10 CMYK PROCESS 15.000000 100.000000 90.000000 10.000000 C=0 M=90 J=85 N=0 CMYK PROCESS 0.000000 90.000000 85.000000 0.000000 C=0 M=80 J=95 N=0 CMYK PROCESS 0.000000 80.000000 95.000000 0.000000 C=0 M=50 J=100 N=0 CMYK PROCESS 0.000000 50.000000 100.000000 0.000000 C=0 M=35 J=85 N=0 CMYK PROCESS 0.000000 35.000000 85.000000 0.000000 C=5 M=0 J=90 N=0 CMYK PROCESS 5.000000 0.000000 90.000000 0.000000 C=20 M=0 J=100 N=0 CMYK PROCESS 20.000000 0.000000 100.000000 0.000000 C=50 M=0 J=100 N=0 CMYK PROCESS 50.000000 0.000000 100.000000 0.000000 C=75 M=0 J=100 N=0 CMYK PROCESS 75.000000 0.000000 100.000000 0.000000 C=85 M=10 J=100 N=10 CMYK PROCESS 85.000000 10.000000 100.000000 10.000000 C=90 M=30 J=95 N=30 CMYK PROCESS 90.000000 30.000000 95.000000 30.000000 C=75 M=0 J=75 N=0 CMYK PROCESS 75.000000 0.000000 75.000000 0.000000 C=80 M=10 J=45 N=0 CMYK PROCESS 80.000000 10.000000 45.000000 0.000000 C=70 M=15 J=0 N=0 CMYK PROCESS 70.000000 15.000000 0.000000 0.000000 C=85 M=50 J=0 N=0 CMYK PROCESS 85.000000 50.000000 0.000000 0.000000 C=100 M=95 J=5 N=0 CMYK PROCESS 100.000000 95.000000 5.000000 0.000000 C=100 M=100 J=25 N=25 CMYK PROCESS 100.000000 100.000000 25.000000 25.000000 C=75 M=100 J=0 N=0 CMYK PROCESS 75.000000 100.000000 0.000000 0.000000 C=50 M=100 J=0 N=0 CMYK PROCESS 50.000000 100.000000 0.000000 0.000000 C=35 M=100 J=35 N=10 CMYK PROCESS 35.000000 100.000000 35.000000 10.000000 C=10 M=100 J=50 N=0 CMYK PROCESS 10.000000 100.000000 50.000000 0.000000 C=0 M=95 J=20 N=0 CMYK PROCESS 0.000000 95.000000 20.000000 0.000000 C=25 M=25 J=40 N=0 CMYK PROCESS 25.000000 25.000000 40.000000 0.000000 C=40 M=45 J=50 N=5 CMYK PROCESS 40.000000 45.000000 50.000000 5.000000 C=50 M=50 J=60 N=25 CMYK PROCESS 50.000000 50.000000 60.000000 25.000000 C=55 M=60 J=65 N=40 CMYK PROCESS 55.000000 60.000000 65.000000 40.000000 C=25 M=40 J=65 N=0 CMYK PROCESS 25.000000 40.000000 65.000000 0.000000 C=30 M=50 J=75 N=10 CMYK PROCESS 30.000000 50.000000 75.000000 10.000000 C=35 M=60 J=80 N=25 CMYK PROCESS 35.000000 60.000000 80.000000 25.000000 C=40 M=65 J=90 N=35 CMYK PROCESS 40.000000 65.000000 90.000000 35.000000 C=40 M=70 J=100 N=50 CMYK PROCESS 40.000000 70.000000 100.000000 50.000000 C=50 M=70 J=80 N=70 CMYK PROCESS 50.000000 70.000000 80.000000 70.000000 Gris 1 C=0 M=0 J=0 N=100 CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 C=0 M=0 J=0 N=90 CMYK PROCESS 0.000000 0.000000 0.000000 89.999400 C=0 M=0 J=0 N=80 CMYK PROCESS 0.000000 0.000000 0.000000 79.998800 C=0 M=0 J=0 N=70 CMYK PROCESS 0.000000 0.000000 0.000000 69.999700 C=0 M=0 J=0 N=60 CMYK PROCESS 0.000000 0.000000 0.000000 59.999100 C=0 M=0 J=0 N=50 CMYK PROCESS 0.000000 0.000000 0.000000 50.000000 C=0 M=0 J=0 N=40 CMYK PROCESS 0.000000 0.000000 0.000000 39.999400 C=0 M=0 J=0 N=30 CMYK PROCESS 0.000000 0.000000 0.000000 29.998800 C=0 M=0 J=0 N=20 CMYK PROCESS 0.000000 0.000000 0.000000 19.999700 C=0 M=0 J=0 N=10 CMYK PROCESS 0.000000 0.000000 0.000000 9.999100 C=0 M=0 J=0 N=5 CMYK PROCESS 0.000000 0.000000 0.000000 4.998800 Couleurs vives 1 C=0 M=100 J=100 N=0 CMYK PROCESS 0.000000 100.000000 100.000000 0.000000 C=0 M=75 J=100 N=0 CMYK PROCESS 0.000000 75.000000 100.000000 0.000000 C=0 M=10 J=95 N=0 CMYK PROCESS 0.000000 10.000000 95.000000 0.000000 C=85 M=10 J=100 N=0 CMYK PROCESS 85.000000 10.000000 100.000000 0.000000 C=100 M=90 J=0 N=0 CMYK PROCESS 100.000000 90.000000 0.000000 0.000000 C=60 M=90 J=0 N=0 CMYK PROCESS 60.000000 90.000000 0.003100 0.003100 Adobe PDF library 15.00

OCS-01 phase 2 study results in DME

 

Interviews with Dr. Pravin U. Dugel

Dr. Pravin U. Dugel
DME Treatments and Challenges

Dr. Pravin U. Dugel
OCS-01 Phase 2 Study Results

Dr. Pravin U. Dugel
OCS-01 Phase 2 Study : Case Studies

OCS-01 is an investigational drug and has not received regulatory approval for commercial use in any country. Some of the statements in the video reflect Dr. Pravin U. Dugel’s perception of the results from the phase 2 clinical trial in DME and some of the forward-looking statements reflect his opinion on potential future use of OCS-01 based on his clinical experience.

OCS-01: A potential paradigm
shift in DME treatment

One of our most advanced product candidates, OCS-01, has successfully completed a Phase 2 trial in DME (DX-211) with 144 patients providing the first proof-of-concept for a topical drug effect on a chronic retinal disease. If approved in DME, it has the potential to provide a new and potentially the FIRST non-invasive option for patients.

 

OCS-01 also successfully completed another Phase 2 trial in Inflammation and Pain following cataract surgery. Following the completion of both Phase 2 trials, an End of Phase 2 meeting was conducted with FDA and the product candidate is now moving into phase III in both indications.

 

OCS-01 has been developed from Oculis’ solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.

OCS-01: A potential treatment
for Post-cataract Surgery Inflammation

 

OCS-01 successfully completed a Phase 2 trial in Inflammation and Pain following cataract surgery (SKYGGN trial) with 153 patients providing the first proof-of-concept of a once daily topical steroid. A long-acting topical solution, such as OCS-01, has the potential of reducing the burden of administration given that patients undergoing cataract surgery are usually on several medications daily.

 

OCS-01 also successfully completed another Phase 2 trial in DME. Following the completion of both Phase 2 trials, an End of Phase 2 meeting was conducted with FDA and the product candidate is now moving into phase III in both indications.

 

OCS-01 has been developed from Oculis’ solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.

OCS-02: THE POTENTIAL OF
topical anti-TNF alpha
therapy for ophthalmic
indications

The compound, named OCS-02, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials including two controlled studies under IND. The studies demonstrated a promising profile for treating inflammatory conditions of the anterior segment of the eye including Uveitis and Dry Eye Disease.